Applicability of Histoculture Drug Response Assays in Colorectal Cancer Chemotherapy

The present study, using the histoculture drug response assay (HDRA) compared chemosensitivity with the clinical response of a treatment regime in patients with advanced colorectal cancer (CRC). A total of 324 patients with primary CRC were prospectively enrolled. HDRAs were performed using seven co...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2012-08, Vol.32 (8), p.3581-3586
Main Authors: YOON, Yongsik, CHANWOOKKIM, SEONAEROH, HYUNGCHO, Dong, GYUPYOKIM, YONG SANG HONG, TAE WON KIM, MOON BO KIM, JIN CHEON KIM
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Colorectal Neoplasms - drug therapy
Drug Screening Assays, Antitumor
Female
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Male
Medical sciences
Middle Aged
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Tumor Cells, Cultured
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The present study, using the histoculture drug response assay (HDRA) compared chemosensitivity with the clinical response of a treatment regime in patients with advanced colorectal cancer (CRC). A total of 324 patients with primary CRC were prospectively enrolled. HDRAs were performed using seven combinations of anticancer drugs, including 5-fluorouracil with leucovorin (FL), FL with oxaliplatin (FOLFOX), irinotecan (FOLFIRI), and their combinations with bevacizumab and cetuximab. Among 324 HDRA results, tumor inhibition rates of regimes using FOLFOX (34.2-39.2%) were higher than those using FOLFIRI (24.2-32.7%, p
ISSN:0250-7005
1791-7530